Respiratory and Inflammation, Bioscience Department, AstraZeneca R&D Charnwood, Loughborough, UK,
J Cachexia Sarcopenia Muscle. 2013 Jun;4(2):157-69. doi: 10.1007/s13539-012-0097-z. Epub 2013 Jan 24.
During aging, there is a decreased ability to maintain skeletal muscle mass and function (sarcopenia). Such changes in skeletal muscle are also co-morbidities of diseases including cancer, congestive heart failure and chronic obstructive pulmonary disease. The loss of muscle mass results in decreased strength and exercise tolerance and reduced ability to perform daily activities. Pharmacological agents addressing these pathologies could have significant clinical impact, but their identification requires understanding of mechanisms driving myotube formation (myogenesis) and atrophy and provision of relevant assays. The aim of this study was to develop robust in vitro methods to study human myogenesis.
Satellite cells were isolated by digestion of post-mortem skeletal muscle and selection using anti-CD56 MicroBeads. CD56(+) cell-derived myotubes were quantified by high content imaging of myosin heavy chains. TaqMan-polymerase chain reaction arrays were used to quantify expression of 41 selected genes during differentiation. The effects of activin receptor agonists and tumour necrosis factor alpha (TNFα) on myogenesis and gene expression were characterised.
Large-scale isolation of CD56(+) cells enabled development of a quantitative myogenesis assay with maximal myotube formation 3 days after initiating differentiation. Gene expression analysis demonstrated expression of 19 genes changed substantially during myogenesis. TNFα and activin receptor agonists inhibited myogenesis and downregulated gene expression of muscle transcription factors, structural components and markers of oxidative phenotype, but only TNFα increased expression of pro-inflammatory markers.
We have developed methods for large-scale isolation of satellite cells from muscle and quantitative assays for studying human myogenesis. These systems may prove useful as part of a screening cascade designed to identify therapeutic agents for improving muscle function.
随着年龄的增长,维持骨骼肌量和功能(肌肉减少症)的能力会下降。骨骼肌的这些变化也是癌症、充血性心力衰竭和慢性阻塞性肺疾病等疾病的合并症。肌肉量的减少导致力量和运动耐量下降,以及日常活动能力降低。针对这些病理的药物治疗可能具有重要的临床影响,但需要了解驱动肌管形成(成肌作用)和萎缩的机制,并提供相关的检测方法。本研究旨在开发研究人类成肌作用的稳健体外方法。
通过死后骨骼肌的消化和使用抗 CD56 微珠进行选择,分离卫星细胞。通过肌球蛋白重链的高内涵成像定量 CD56(+) 细胞衍生的肌管。使用 TaqMan 聚合酶链反应阵列定量分化过程中 41 个选定基因的表达。研究了激活素受体激动剂和肿瘤坏死因子 α(TNFα)对成肌作用和基因表达的影响。
大规模分离 CD56(+) 细胞使定量成肌作用测定得以发展,在开始分化后 3 天达到最大肌管形成。基因表达分析表明,19 个基因在成肌过程中表达发生了显著变化。TNFα 和激活素受体激动剂抑制成肌作用,并下调肌肉转录因子、结构成分和氧化表型标志物的基因表达,但只有 TNFα 增加了促炎标志物的表达。
我们已经开发出从肌肉中大规模分离卫星细胞和研究人类成肌作用的定量测定方法。这些系统可能有助于作为旨在识别改善肌肉功能的治疗剂的筛选级联的一部分。